{"entity":{"id":"nct01360554","kind":"trial","name":"ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial of Dacomitinib and Erlotinib in Non-small-cell lung cancer, run by Pfizer, completed.","summary":"ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT01360554 by Pfizer, with 878 participants recorded, started 2011-06-16 and reaching its primary completion in 2013-09-30. Interventions recorded: Dacomitinib (PF-00299804), Active Comparator (erlotinib), Placebo erlotinib, Placebo PF00299804. Conditions recorded: Non-Small Cell Lung Cancer.\n\nLinked to the drug Dacomitinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT01360554","url":"https://clinicaltrials.gov/study/NCT01360554"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["dacomitinib","erlotinib"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01360554","phase":"3","setting":"Archer 1009:a Randomized, Double Blind Phase 3 Efficacy And Safety Study Of Pf-00299804 (Dacomitinib) Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy","sponsor":"Pfizer","started":"2011-06-16","yearReported":2017,"enrolled":878,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-Free Survival (PFS) Per Independent Radiologic Review.","primary":true,"unit":"months","arms":[{"name":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","n":439,"value":2.6,"note":"95% CI 1.9 to 2.8; Figures from the ClinicalTrials.gov results section (first posted 2017-05-24), not from a publication"},{"name":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","n":439,"value":2.5,"note":"95% CI 1.9 to 2.8"}],"hr":0.933,"ci":[0.797,1.093],"p":"0.195","source":"https://clinicaltrials.gov/study/NCT01360554?tab=results"},{"endpoint":"Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants.","primary":true,"unit":"months","arms":[{"name":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","n":256,"value":2.6,"note":"95% CI 1.9 to 2.9; Figures from the ClinicalTrials.gov results section (first posted 2017-05-24), not from a publication"},{"name":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","n":263,"value":2.5,"note":"95% CI 1.9 to 3.0"}],"hr":1.037,"ci":[0.848,1.268],"p":"0.643","source":"https://clinicaltrials.gov/study/NCT01360554?tab=results"},{"endpoint":"Overall Survival (OS).","unit":"months","arms":[{"name":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","n":439,"value":7.9,"note":"95% CI 6.8 to 9.0; Figures from the ClinicalTrials.gov results section (first posted 2017-05-24), not from a publication"},{"name":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","n":439,"value":8.3,"note":"95% CI 7.4 to 9.7"}],"hr":1.026,"ci":[0.887,1.188],"p":"0.638","source":"https://clinicaltrials.gov/study/NCT01360554?tab=results"}]},"route":"/trials/nct01360554/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"dacomitinib","kind":"drug","name":"Dacomitinib","route":"/drugs/dacomitinib/"},{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}